不同剂量阿托伐他汀对国人颈动脉粥样硬化影响的Meta分析

吉林大学学报(医学版) ›› 2013, Vol. 39 ›› Issue (2): 313-317.

不同剂量阿托伐他汀对国人颈动脉粥样硬化影响的Meta分析

刘松岩¹,张晓君²,才华¹,杨丽亚^1,丁晓娜¹,常颖^1

1.吉林大学中日联谊医院神经内科,吉林长春130033；2.山东省滕州市人民中心医院神经内科，山东滕州 277500

收稿日期:2012-09-26 出版日期:2013-03-28 发布日期:2013-03-28
通讯作者: 常颖（Tel:0431-84995820，E-mail:yingchang1971@126.com） E-mail:yingchang1971@126.com
作者简介:刘松岩(1966-)，女，吉林省松原市人，教授,主任医师，医学博士，博士研究生导师，主要从事认知障碍和癫痫的基础与临床研究。
基金资助:
吉林省科技厅自然科学基金项目资助课题(20111587);吉林省科技厅科技发展计划项目资助课题(2011743，20120705);吉林大学基本科研业务费项目资助课题(2012211)

Meta-analysis on influence of different doses of atorvastatin on carotid atherosclerosis in Chinese

LIU Song-yan¹，ZHANG Xiao-jun²，CAI Hao¹，YANG Li-ya¹，DING Xiao-na¹，CHANG Ying¹

1.Department of Neurology,China-Japan Union Hospital,Jilin University,Changchun 130033,China；2.Department of Neurology,People’s Hospital of Tengzhou City,Tengzhou 277500,China

Received:2012-09-26 Online:2013-03-28 Published:2013-03-28

摘要/Abstract

摘要： 目的：分析不同剂量阿托伐他汀对国人颈动脉粥样硬化及缺血性脑卒中的影响，寻求安全有效的、适合中国人群应用的阿托伐他汀剂量，为预防缺血性脑卒中提供理论依据。方法：计算机检索PubMed、Medline、中国知网、维普中文科技期刊和中国生物医学文献数据库等在1990—2011年关于阿托伐他汀在脑卒中应用的随机对照试验（RCTs）文章，由2名评价员独立筛选、评价文献和提取数据；应用系统评价软件Revman 5.0及SPSS 13.0计算相关指标绘制图表，并针对不同剂量阿托伐他汀对颈动脉内膜中层厚度（IMT）、低密度脂蛋白胆固醇（LDL-C）和不良反应的影响进行Meta分析。结果：中国人群普遍的阿托伐他汀应用剂量为10和20 mg，大剂量阿托伐他汀对比研究资料尚不充分。Meta分析显示，20 mg阿托伐他汀组IMT变化优于10 mg组，MD=－0.21,95%CI［－0.25，－0.17］； 20 mg组LDL-C值低于10 mg组，MD=0.52，95%CI［0.44,0.61］；2组不良反应未见明显差异。结论：阿托伐他汀用于预防脑卒中时，在IMT变化和降低LDL-C方面，阿托伐他汀20 mg优于10 mg，且在不良反应方面无明显差异。

关键词: 阿托伐他汀, 颈动脉粥样硬化, 缺血性卒中

Abstract: Abstract:Objective To analyze the influence of different doses of atorvastatin on carotid atherosclerosis and ischemic stroke in Chinese and to find safe and effective dose of atorvastatin to prevent ischemic stroke preferably for Chinese population. Methods PubMed，Medline，CNKI，VIP Chinese Science and Technology Journals were used to search randomized controlled trails(RCTs) about atovastatin on anti-atherosclerosis and stroke prevention from 1990 to 2011 by computer.The Meta-analysis evaluation software Revman 5.0 was applied，and some indicators were calculated by SPSS 13.0.The changes of intima-media thickness(IMT) and low density lipoprotein-cholesterol(LDL-C),recurrence of ischemic stroke and side effects after treated with different doses of atorvastatin were compared with Meta-analysis. Results 10 and 20 mg atovastatin were widely used by Chinese.Comparative research on megadose atovastatin was still not fully enough.Meta-analysis showed that 20 mg atovastatin was more effective than 10 mg(P＜0.05) in the aspects of anti-atherosclerosis，and the change of IMT in 20 mg atovastatin group was better than 10 mg group,MD=－0.21,95%CI ［－0.25，－0.17］,and the LDL-C level in 20 mg group was lower than that in 10 mg group,MD=0.52，95%CI［0.44，0.61］.At the same time there were no significant differences on adverse effects between two groups.Conclusion 20 mg atovastatin is more better than 10 mg on the changes of IMT,and reduction of LDL-C.There is no difference in adverse effects between 20 and 10 mg atovastatin.

Key words: atorvastatin, carotid atherosclerosis, ischemic stroke

中图分类号:

刘松岩,张晓君,才华,杨丽亚,丁晓娜,常颖. 不同剂量阿托伐他汀对国人颈动脉粥样硬化影响的Meta分析[J]. 吉林大学学报(医学版), 2013, 39(2): 313-317.

LIU Song-yan，ZHANG Xiao-jun，CAI Hao，YANG Li-ya，DING Xiao-na，CHANG Ying . Meta-analysis on influence of different doses of atorvastatin on carotid atherosclerosis in Chinese[J]. Journal of Jilin University Medicine Edition, 2013, 39(2): 313-317.

[1]	杜彪, 谢星星, 张杰, 范小冬, 叶云. 瑞舒伐他汀治疗中国原发性高胆固醇血症患者疗效与安全性的系统评价[J]. 吉林大学学报(医学版), 2016, 42(05): 968-974.
[2]	. 阿托伐他汀对同型半胱氨酸作用下人脐静脉内皮细胞Bcl-2启动子区甲基化水平的影响及其抗动脉粥样硬化机制[J]. 吉林大学学报(医学版), 2014, 40(05): 1002-1006.
[3]	石博，黄可欣，叶保国，张艳，黄可敬. 阿托伐他汀预处理对大鼠心肌缺血再灌注后不同时间点心肌组织中HIF-α和VEGF表达的影响[J]. 吉林大学学报(医学版), 2013, 39(6): 1159-1163.
[4]	黄可欣, 石博, 叶保国, 宋雪松 . 阿托伐他汀对心肌缺血再灌注损伤大鼠心肌酶和心肌细胞凋亡的影响及其心肌保护作用机制[J]. 吉林大学学报(医学版), 2013, 39(5): 923-927.
[5]	张敏\|宁亚媛\|张晶\|陈丽娟. ActRⅡA介导阿托伐他汀对动脉粥样硬化的治疗作用[J]. J4, 2012, 38(1): 54-57.
[6]	林述凯, 石秋艳, 王淑歌, 田广平, 张国志. 阿托伐他汀对实验性自身免疫性脑脊髓炎大鼠脊髓内NF-κB表达的影响[J]. J4, 2011, 37(4): 607-611.
[7]	杨玉双，李学宇，麻薇，杨萍. 兔动脉粥样硬化模型中NO和PAI-1的表达及阿托伐他汀的干预作用[J]. J4, 2007, 33(4): 671-674.
[8]	王晓美，秦玲，李洋，黄可欣. 阿托伐他汀对家兔动脉粥样硬化模型PPARγ及MMP-9表达的影响[J]. J4, 2007, 33(3): 480-482.